Skip to main content
Full access
Articles
Published Online: 13 August 2016

Altered Expression of ARP2/3 Complex Signaling Pathway Genes in Prefrontal Layer 3 Pyramidal Cells in Schizophrenia

Abstract

Objective:

Lower dendritic spine density on layer 3 pyramidal cells in the dorsolateral prefrontal cortex (DLPFC) appears to contribute to cognitive dysfunction in schizophrenia, whereas psychosis is associated with excessive dopamine release in the striatum. These findings may be related via excitatory projections from the DLPFC to the ventral mesencephalon, the location of dopamine cells projecting to the striatum. Consistent with this hypothesis, deletion of the actin-related protein-2/3 (ARP2/3) complex, which regulates the actin cytoskeleton supporting dendritic spines, produced spine loss in cortical pyramidal cells and striatal hyperdopaminergia in mice. The authors sought to determine whether the ARP2/3 complex is altered in schizophrenia.

Method:

In matched pairs of schizophrenia and comparison subjects, transcript levels of ARP2/3 complex signaling pathway were assessed in laser-microdissected DLPFC layer 3 and 5 pyramidal cells and layer 3 parvalbumin interneurons, and in total DLPFC gray matter.

Results:

Transcript levels of ARP2/3 complex subunits and of nucleation promotion factors that regulate the ARP2/3 complex were significantly lower in DLPFC layer 3 and 5 pyramidal cells in schizophrenia. In contrast, these transcripts were unaltered, or only modestly changed, in parvalbumin interneurons and DLPFC gray matter.

Conclusions:

Down-regulation of the ARP2/3 complex signaling pathway, a common final pathway for multiple signaling cascades that regulate the actin cytoskeleton, would compromise the structural stability of spines, leading to their loss. In concert with findings from deletion of the ARP2/3 complex in mice, these findings support the idea that spine deficits in the DLPFC may contribute to subcortical hyperdopaminergia in schizophrenia.

Formats available

You can view the full content in the following formats:

Supplementary Material

File (appi.ajp.2016.16020204.ds001.pdf)

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 163 - 171
PubMed: 27523502

History

Received: 15 February 2016
Revision received: 12 April 2016
Accepted: 20 May 2016
Published online: 13 August 2016
Published in print: February 01, 2017

Authors

Affiliations

Dibyadeep Datta, Ph.D.
From the Departments of Neuroscience and Psychiatry, Translational Neuroscience Program, University of Pittsburgh School of Medicine, Pittsburgh.
Dominique Arion, Ph.D.
From the Departments of Neuroscience and Psychiatry, Translational Neuroscience Program, University of Pittsburgh School of Medicine, Pittsburgh.
Kaitlyn M. Roman, B.S.
From the Departments of Neuroscience and Psychiatry, Translational Neuroscience Program, University of Pittsburgh School of Medicine, Pittsburgh.
David W. Volk, M.D., Ph.D.
From the Departments of Neuroscience and Psychiatry, Translational Neuroscience Program, University of Pittsburgh School of Medicine, Pittsburgh.
David A. Lewis, M.D.
From the Departments of Neuroscience and Psychiatry, Translational Neuroscience Program, University of Pittsburgh School of Medicine, Pittsburgh.

Notes

Address correspondence to Dr. Lewis ([email protected]).
Presented in part at the third annual meeting of the Molecular Psychiatry Association, San Francisco, Oct. 30 to Nov. 1, 2015.

Competing Interests

Dr. Lewis has received investigator-initiated research support from Pfizer and has served as a consultant in the areas of target identification and validation and new compound development for Autifony, Bristol-Myers Squibb, Concert Pharmaceuticals, and Sunovion. The other authors report no financial relationships with commercial interests.

Funding Information

National Institute of Mental Health10.13039/100000025: MH043784, MH103204, MH100066
Supported by NIH grants MH103204 (to Dr. Lewis), MH043784 (to Dr. Lewis), and MH100066 (to Dr. Volk).

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share